These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 23927624)

  • 1. An analysis of characteristics of subjects examined for incretin effects on pancreatic pathology.
    Harja E; Lord J; Skyler JS
    Diabetes Technol Ther; 2013 Aug; 15(8):609-18. PubMed ID: 23927624
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Elevated amylase and lipase levels in patients using glucagonlike peptide-1 receptor agonists or dipeptidyl-peptidase-4 inhibitors in the outpatient setting.
    Lando HM; Alattar M; Dua AP
    Endocr Pract; 2012; 18(4):472-7. PubMed ID: 22440997
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies.
    Elashoff M; Matveyenko AV; Gier B; Elashoff R; Butler PC
    Gastroenterology; 2011 Jul; 141(1):150-6. PubMed ID: 21334333
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Case report of acute necrotizing pancreatitis associated with combination treatment of sitagliptin and exenatide.
    Iyer SN; Drake AJ; West RL; Mendez CE; Tanenberg RJ
    Endocr Pract; 2012; 18(1):e10-3. PubMed ID: 22068258
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pancreatitis associated with incretin-based therapies.
    Iyer SN; Tanenberg RJ; Mendez CE; West RL; Drake AJ
    Diabetes Care; 2013 Apr; 36(4):e49. PubMed ID: 23520376
    [No Abstract]   [Full Text] [Related]  

  • 6. [Incretin related agents for treatment of diabetes mellitus].
    Miyagawa J; Miuchi M; Nanba M
    Nihon Naika Gakkai Zasshi; 2009 Apr; 98(4):809-16. PubMed ID: 19472544
    [No Abstract]   [Full Text] [Related]  

  • 7. Distinguishing among incretin-based therapies. Safety, tolerability, and nonglycemic effects of incretin-based therapies.
    Campbell RK; Cobble ME; Reid TS; Shomali ME
    J Fam Pract; 2010 Sep; 59(9 Suppl 1):S20-7. PubMed ID: 20824236
    [TBL] [Abstract][Full Text] [Related]  

  • 8. GLP-1-based therapies: the dilemma of uncertainty.
    Spranger J; Gundert-Remy U; Stammschulte T
    Gastroenterology; 2011 Jul; 141(1):20-3. PubMed ID: 21723985
    [No Abstract]   [Full Text] [Related]  

  • 9. [Therapeutic use and adverse events of incretin-related drugs].
    Ishikawa M; Yamada Y
    Nihon Rinsho; 2012 May; 70 Suppl 3():699-702. PubMed ID: 22768601
    [No Abstract]   [Full Text] [Related]  

  • 10. Use of a claims-based active drug safety surveillance system to assess the risk of acute pancreatitis with exenatide or sitagliptin compared to metformin or glyburide.
    Dore DD; Seeger JD; Arnold Chan K
    Curr Med Res Opin; 2009 Apr; 25(4):1019-27. PubMed ID: 19278373
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Journal withdraws article after complaints from drug manufacturers.
    Hawkes N
    BMJ; 2011 Apr; 342():d2335. PubMed ID: 21482597
    [No Abstract]   [Full Text] [Related]  

  • 12. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes.
    Drucker DJ; Nauck MA
    Lancet; 2006 Nov; 368(9548):1696-705. PubMed ID: 17098089
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The potential risks of pancreatitis and pancreatic cancer with GLP-1-based therapies are far outweighed by the proven and potential (cardiovascular) benefits.
    Ryder RE
    Diabet Med; 2013 Oct; 30(10):1148-55. PubMed ID: 24073725
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pro- or anti-inflammatory properties of the adipokine dipeptidyl peptidase-4?
    Xu L; Spinas GA; Niessen M
    Gastroenterology; 2011 Dec; 141(6):e17. PubMed ID: 22036848
    [No Abstract]   [Full Text] [Related]  

  • 15. One year of sitagliptin treatment protects against islet amyloid-associated β-cell loss and does not induce pancreatitis or pancreatic neoplasia in mice.
    Aston-Mourney K; Subramanian SL; Zraika S; Samarasekera T; Meier DT; Goldstein LC; Hull RL
    Am J Physiol Endocrinol Metab; 2013 Aug; 305(4):E475-84. PubMed ID: 23736544
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Marked expansion of exocrine and endocrine pancreas with incretin therapy in humans with increased exocrine pancreas dysplasia and the potential for glucagon-producing neuroendocrine tumors.
    Butler AE; Campbell-Thompson M; Gurlo T; Dawson DW; Atkinson M; Butler PC
    Diabetes; 2013 Jul; 62(7):2595-604. PubMed ID: 23524641
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [New drugs; exenatide and sitagliptin].
    van Bronswijk H; Dubois EA; Pijl H; Cohen AF
    Ned Tijdschr Geneeskd; 2008 Apr; 152(15):876-9. PubMed ID: 18512528
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel therapies for the management of type 2 diabetes mellitus: Part 2. Addressing the incretin defect in the clinical setting in 2013.
    Grunberger G
    J Diabetes; 2013 Sep; 5(3):241-53. PubMed ID: 23489968
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Focus on incretin-based therapies: targeting the core defects of type 2 diabetes.
    Jellinger PS
    Postgrad Med; 2011 Jan; 123(1):53-65. PubMed ID: 21293084
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Incretin treatment and risk of pancreatitis in patients with type 2 diabetes mellitus: systematic review and meta-analysis of randomised and non-randomised studies.
    Li L; Shen J; Bala MM; Busse JW; Ebrahim S; Vandvik PO; Rios LP; Malaga G; Wong E; Sohani Z; Guyatt GH; Sun X
    BMJ; 2014 Apr; 348():g2366. PubMed ID: 24736555
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.